For immediate release

13 August 2024

Full year reported NPATA US$2.91 billion1,2
Up 15% at constant currency3
Strong CSL Behring performance led by Ig
FINANCIAL HIGHLIGHTS 4• Revenue $14.8 billion, up 11% at CC3• NPAT $2.64 billion1, up 20%- NPAT $2.75 billion1 at CC3, up 25%• NPATA $2.91 billion1,2, up 11%• NPATA $3.01 billion1,2 at CC3, up 15%• NPATA1,2 earnings per share $6.022, up 11%• Final dividend 5 of US$1.45 per share-Total full year dividend US$2.64, up 12%
Converted to Australian currency, the total full year dividend is approximately A$4.00
per share, up 10%• NPATA2,4 for FY25 anticipated to be in the range of approximately $3.2 billion to $3.3 billion2 at
CC3, up approximately 10-13%.

CSL Limited (ASX:CSL; USOTC:CSLLY) today announces a reported net profit after tax of $2.64
billion1 for the 12 months ended 30 June 2024, up 25% on a constant currency basis3. NPATA was$2.91 billion1,2, up 15% on a constant currency basis to $3.01 billion1,2,3.
Dr. Paul McKenzie, CSL’s Chief Executive Officer and Managing Director said, “I am pleased toreport a strong result for the 2024 financial year led by CSL Behring. Our largest franchise, theimmunoglobulins portfolio, delivered exceptional growth driven by significant patient demand
and the recovery in CSL Behring’s gross margin is progressing to plan.
“CSL Seqirus outperformed the market in a challenging environment driven by the adjuvanted
influenza vaccine FLUAD®.

“CSL Vifor continues to grow iron volume in Europe despite generic entrants and we remain
confident in our plan to drive long-term value from this business.
“Overall, this result demonstrates that we are delivering on the strategic objectives that wecommunicated at our Capital Markets Day in October last year. We remain confident in ourdouble-digit earnings growth target over the medium-term, reflecting a disciplined focus on
the execution of our strategy.

PERFORMANCECSL Behring
Total revenue was $10,608 million, up 14%3 when compared to the prior comparable period.
Immunoglobulin (Ig) product sales of $5,666 million, increased 20%3 with strong growthrecorded across all geographies.
PRIVIGEN® / INTRAGAM® (Immune Globulin Intravenous (Human), 10% Liquid) sales grew 21%3
led by improved supply and strong patient demand.
HIZENTRA® (Immune Globulin Subcutaneous (Human), 20% Liquid) sales were up 19%3 driven byincreasing patient diagnosis rates and the launch of the 50mL pre-filled syringe. HIZENTRA®
continues to be the clear market leader for subcutaneous immunoglobulin.
Underlying demand for Ig continues to be strong due to significant patient needs in core
indications – namely Primary Immune Deficiency, Secondary Immune Deficiency and Chronic
Inflammatory Demyelinating Polyneuropathy (CIDP).
Albumin sales of $1,209 million, were up 12%3.
Sales were strong in emerging markets with solid growth in China, the US and Europe.
Haemophilia product sales of $1,313 million increased 10%3.
IDELVION®, CSL Behring’s novel long-acting recombinant factor IX product achieved growth of
10%3 and continues to be the market leader and standard of care in all key markets.
HEMGENIX®, the first gene therapy treatment for haemophilia B launched in FY23, continues tobuild momentum with patient infusions across the US and Europe, following recent
reimbursement approvals in EU, UK, Switzerland and Canada.
Specialty products sales of $1,940 million, were up 6%3 predominately led by HAEGARDA® andKCENTRA®.
HAEGARDA®, our therapy for patients with Hereditary Angioedema, increased 12%, due tocontinued strong patient demand and a strong performance in Europe and Japan.

2

KCENTRA® (4 factor prothrombin complex concentrate) recorded sales growth of 5%3, as it
continues to further penetrate the Warfarin reversal market in the US with some volume impact
from a competitor launch.
PlasmaThe momentum in plasma collections has continued and the cost per litre, which includes
donor compensation and labour, has reduced further.
Significant progress has been made on digital transformation with an enhanced focus onplasma centre efficiencies.
The roll out of the RIKA plasmapheresis device is on track to be completed by the end of the2025 financial year.
Furthermore, the individualised nomogram has been approved by the FDA and is expected to
be deployed throughout FY25.
The yield initiatives in the plasma manufacturing process are progressing to plan.
CSL Seqirus
Total revenue of $2,128 million, was up 4%3 driven by the adjuvanted influenza vaccine FLUAD®,
which increased by 14%3.
This growth was achieved against a backdrop of reduced rates of immunisation and highlights
the strength of CSL Seqirus' differentiated product portfolio.
During the period:••

Self-amplifying mRNA vaccine for COVID (KOSTAIVE®) was approved by Japan’s Ministry ofHealth, Labour and Welfare.
aTIVc, a next generation influenza vaccine combining adjuvant technology with cell-basedmanufacturing, enrolled its last patient in the Phase III clinical study in January 2024.

CSL Vifor
Total revenue was $2,064 million. The prior comparable period included 11 months of revenue
following the acquisition of Vifor Pharma in August 2022.
During the period:••••

Volume of iron in Europe continued to grow despite the introduction of follow-on products
in some European markets.
FERINJECT® was launched in China.
MIRCERA®, the long-acting erythropoiesis-stimulating agent, performed strongly as patient
conversion in the US continued.
TAVNEOS® was successfully launched in multiple European countries.

3Realised synergies have significantly exceeded expectations at the time of the acquisition.
Expense Performance
Research and development (R&D) expenses were $1,428 million7,8, up 12%3 when compared tothe prior comparable period and at the low end of our 10-11% of revenue guidance.
Selling and marketing expenses (S&M) were $1,556 million7,8, up 5%3 in comparison to the priorcomparable period. The increase was mainly due to higher labour costs and additional
expenses to support upcoming commercial launches.
General and administrative (G&A) expenses were $825 million8, down 6%3 due to efficiencies
generated from the centralisation of the group’s Enabling Functions and reduced foreignexchange impacts.
Depreciation and amortisation (D&A) expense (excluding acquired intellectual property) was$637 million, up 7%3..
Net finance costs were $437 million8, up 7%3. The increase in net finance costs was due to
twelve months of increased debt to fund the CSL Vifor acquisition and higher interest rates on
floating rate debt.
Financial position
Cashflow from operations was $2,764 million, up 6%. The increase reflected the higher
profitability and overall growth in sales partly offset by an increase in working capital reflecting
a strong finish to the year in CSL Behring.
Capital expenditure for plant, property and equipment was $849 million, down 31% reflecting
the completion of major capital projects in the earlier periods.
CSL’s balance sheet remains in a strong position with net assets of $19,401 million and net debt
to EBITDA at 2.2 times.
Current assets increased by 16% to $10,768 million. The main driver was an increase inreceivables due to the increase in sales and also an increase in inventories due to higher plasmacollection costs and higher plasma production volumes.
Non-current assets of $27,254 million was relatively in-line with the previous year.
Current liabilities increased by 7% to $4,950 million. The increase in trade and other payables
and provisions was offset by the decrease in interest-bearing liabilities and borrowings (bankdebt) and current tax liabilities.
Non-current liabilities were steady at $13,671 million. The decrease in provisions was offset by anincrease in interest-bearing liabilities and borrowings and deferred tax liabilities.

4

During the year, CSL Vifor settled some legacy Vifor Pharma disputes. These settlements wereprovided for as at 30 June 2023 as part of the purchase price accounting for the Vifor Pharma
acquisition. Management expects the settlement payments to be made by the end of the year
ending 30 June 2025.
CSL Board•

New Non-Executive Director:- Elaine Sorg, 35 years’ experience as a senior executive with leading pharmaceuticalcompanies including AbbVie and Eli Lilly, to be effective 1 September 2024People• Roanne Parry appointed Chief Human Resources Officer in January 2024
• David Ross appointed Senior Vice President and General Manager of CSL Seqirus in April
2024• Stephen Marlow appointed Senior Vice President and General Manager of CSL Plasma inApril 2024
Outlook (at FY24 exchange rates)
Commenting on CSL’s outlook, Dr. McKenzie said “The momentum in our CSL Behring businessis expected to continue to be underpinned by the strong patient demand in ourimmunoglobulins franchise.
“We have a number of initiatives underway in plasma collections and our manufacturing
operations that will continue to drive efficiencies and lead to an improving CSL Behring grossmargin.
“We are excited about the potential growth in our transformational gene therapy product forhaemophilia B patients, HEMGENIX® and we are looking forward to bringing our monoclonal
antibody, Garadacimab, for the treatment of HAE, to market in FY25, subject to receiving
regulatory approvals.
“While the market conditions for CSL Seqirus remain challenging, the business is expected tooutperform the market benefitting from its differentiated product portfolio.
“For CSL Vifor, the iron market continues to evolve and we are well positioned for increasedcompetition. We continue to believe in the longer term strategic merits of the business.
“For FY25, revenue growth is anticipated to be approximately 5-7% over FY24 at constantcurrency3. CSL’s NPATA1,2 for FY25 is anticipated to be in the range of approximately $3.2 billion to$3.3 billion at constant currency, representing growth over FY24 of approximately 10-13%”.
“Over the medium term, CSL is in a strong position to continue to deliver annualised double-digit
earnings growth” Dr McKenzie concluded.

5In compiling the company’s financial forecasts for FY25, a number of key factors that may have asignificant impact on guidance have been identified and these have been included in theendnote 6.

FURTHER INFORMATION
Additional details about CSL’s results are included in the company’s 4E statement, investor
presentation slides and webcast, all of which can be found on CSL’s website www.csl.com.
A glossary of medical terms can also be found on the website.
For further information, please contact:
Investors
Chris Cooper
Head of Investor
Relations
CSL Limited

P: +61 455 022 740
E: chris.cooper@csl.com.au

Bernard Ronchi
Director, Investor
Relations
CSL Limited

P: +61 3 9389 3470
E:bernard.ronchi@csl.com.au

Stephen McKeon
Director, Investor
Relations
CSL Limited

Jimmy Baker
Director, Corporate
Communications
CSL Limited

P:+61 402 231 696
P: +61 450 909 211
E:stephen.mckeon@csl.com.au E: jimmy.baker@csl.com.au

6Group Results
Full year ended June

ChangeJun2023

Jun2024

Jun2024

Reported

Reportedat CC3

12,776

14,25914,206

11%

Other Revenue / Income

534541538

1%Total Revenue / Income

13,31014,80014,744

11%

Earnings before Interest, Tax, Depreciation &Amortisation

3,900

4,750

4,837

24%

Depreciation/Amortisation (excluding
acquired intellectual property)

(596)

(637)

(636)

7%

Other acquisition related adjustments

353

84

83

76%

Earnings before Interest and Tax 7

3,657

4,197

4,284

17%

Net Interest Expense

(406)

(437)

(436)

7%

Tax Expense7

(504)

(722)

(708)

40%

NPATA

2,747

3,038

3,139

14%

Amortisation of acquired intellectualproperty(235)(301)(298)

Other acquisition related adjustments

(353)

(84)

(83)

Income tax on the above adjustments

85

61

60

2,244

2,714

2,818

26%

2,610

2,907

3,008

15%

137

131

132

2,194

2,642

2,745

50

72

73

NPATA2 earnings per share1

5.41

6.02

11% 8

NPAT earnings per share (statutory EPS)

4.55

5.47

20%8

Total Dividend (US$)

2.36

2.64

12%8

US$ Millions
Sales

2

Net Profit After Tax%

NPATA attributable to:-Shareholders of CSL Limited-Non-controlling interest

NPAT attributable to:-Shareholders of CSL Limited-Non-controlling interest25%

7

Attributable to CSL shareholders
Statutory net profit after tax (NPAT) before impairment and amortisation of acquired intellectual property, businessacquisition and integration costs and the unwind of the inventory fair value uplift.
3Constant currency (CC) removes the impact of exchange rate movements, facilitating the comparability of operationalperformance. For further detail refer to CSL’s Financial Statements for the Full Year ended June 2024 (Directors Report).
4All figures are expressed in US dollars unless otherwise stated.
5For shareholders with an Australian registered address, the final dividend of US$1.45 per share (approximately A$2.20) isexpected to be paid on 2 October 2024. For shareholders with a New Zealand registered address the final dividend of
US$1.45 per share (approximately NZ $2.41) is expected to be paid on 2 October 2024. The exchange rates will be fixed at
the record date of 10 September 2024. All other shareholders will be paid in US$. CSL also offers shareholders theopportunity to receive dividend payments in US$ by direct credit to a US bank account.
6Factors that could cause actual results to differ materially include: the success or otherwise of CSL’s research anddevelopment activities; factors affecting CSL’s ability to successfully market and sell new and existing products,
including decisions by regulatory authorities regarding approval of CSL’s products and regarding label claims,
competitive developments affecting CSL’s products, and trade buying patterns; factors affecting CSL’s ability to collectplasma, and difficulties or delays in manufacturing; legislation or regulations affecting the manufacturing, distribution,pricing, or reimbursement of CSL’s products, market access for CSL’s products, environmental protection matters, or tax;
litigation or government investigations; fluctuations in interest and currency exchange rates; acquisitions ordivestitures; and CSL’s ability to protects its patents and other intellectual property.
7
Underlying results are adjusted to exclude amortisation of acquired intellectual property, business acquisition andintegrations costs and the unwind of the inventory fair value uplift.
8
At reported currency
128